rs1554985851

chr11-66707534-GTCCATGAGGTAGAGCAGGTCCTGGAACACCTTCTGCAGC-G

Variant summary

Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM4 PP3 PP5_Very_Strong

The NM_006946.4(SPTBN2):c.1596_1634del(p.Glu532_Met544del) variant causes a inframe deletion change involving the alteration of a conserved nucleotide. Variant has been reported in ClinVar as Pathogenic (★★).

• Frequency: Genomes: not found (cov: 32)
• Consequence: SPTBN2 NM_006946.4 inframe_deletion
• Clinical Significance: Pathogenic criteria provided, multiple submitters, no conflicts P:5
• Conservation: PhyloP100: 7.91

Genes affected

SPTBN2 (HGNC:11276): (spectrin beta, non-erythrocytic 2) Spectrins are principle components of a cell's membrane-cytoskeleton and are composed of two alpha and two beta spectrin subunits. The protein encoded by this gene (SPTBN2), is called spectrin beta non-erythrocytic 2 or beta-III spectrin. It is related to, but distinct from, the beta-II spectrin gene which is also known as spectrin beta non-erythrocytic 1 (SPTBN1). SPTBN2 regulates the glutamate signaling pathway by stabilizing the glutamate transporter EAAT4 at the surface of the plasma membrane. Mutations in this gene cause a form of spinocerebellar ataxia, SCA5, that is characterized by neurodegeneration, progressive locomotor incoordination, dysarthria, and uncoordinated eye movements. [provided by RefSeq, Dec 2009]

ACMG classification

Verdict is Pathogenic. Variant got 11 ACMG points.

• PM4: Nonframeshift variant in NON repetitive region in NM_006946.4.
• PP3: No computational evidence supports a deleterious effect, but strongly conserved according to phyloP
• PP5: Variant 11-66707534-GTCCATGAGGTAGAGCAGGTCCTGGAACACCTTCTGCAGC-G is Pathogenic according to our data. Variant chr11-66707534-GTCCATGAGGTAGAGCAGGTCCTGGAACACCTTCTGCAGC-G is described in ClinVar as [Pathogenic]. Clinvar id is 448482.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
SPTBN2	NM_006946.4	c.1596_1634del	p.Glu532_Met544del	inframe_deletion	13/38	ENST00000533211.6

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
SPTBN2	ENST00000533211.6	c.1596_1634del	p.Glu532_Met544del	inframe_deletion	13/38	5	NM_006946.4	P1

Frequencies

GnomAD3 genomes Cov.: 32

We have no GnomAD4 exomes data on this position. Probably position not covered by the project.

GnomAD4 genome Cov.: 32

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:5

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not provided Pathogenic:3

Pathogenic, criteria provided, single submitter	clinical testing	Invitae	Oct 24, 2023	This variant, c.1596_1634del, results in the deletion of 13 amino acid(s) of the SPTBN2 protein (p.Glu532_Met544del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with autosomal dominant spinal cerebellar ataxia type 5 (PMID: 16429157). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 448482). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects SPTBN2 function (PMID: 25057192). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitter	clinical testing	Athena Diagnostics	Nov 16, 2022	This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In multiple families, this variant segregates with spinocerebellar ataxia in an autosomal dominant manner. Assessment of experimental evidence suggests this variant results in abnormal protein function. Studies show that this variant interferes with beta-III spectrin stabilization of glutamate transporters and receptors (PMID: 16429157, 20368622, 25057192). -
Pathogenic, criteria provided, single submitter	clinical testing	Genetic Services Laboratory, University of Chicago	Feb 20, 2018	- -

Spinocerebellar ataxia type 5 Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	Nov 25, 2022	Variant summary: SPTBN2 c.1596_1634del39 (p.Glu532_Met544del) results in an in-frame deletion that is predicted to remove 13 amino acids from the encoded protein. The variant was absent in 236106 control chromosomes. c.1596_1634del39 has been reported in the literature in multiple individuals affected with Spinocerebellar Ataxia 5 from a large 11-generation American kindred (example, Ikeda_2006). These data indicate that the variant is very likely to be associated with disease. At two publications report experimental evidence evaluating an impact on protein function demonstrating, 1. disruption of the normal stabilization of the glutamate transporter EAAT4 at the plasma membrane and 2. a mouse model with features consistent to pathophysiology of human disease (example, Ikeda_2006, Armbrust_2014). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, no assertion criteria provided	literature only	OMIM	Feb 01, 2006	- -

Computational scores

Source: dbNSFP v4.3

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs1554985851; hg19: chr11-66475005;